Amgen (NASDAQ: AMGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Amgen reported 14 open-market sales of 78,049 shares ($29.3m) and 0 open-market purchases, by 6 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 6 November 2026 | Drake Michael V | Director | Grant or award | +114 | — | 6,030 | Form 4 |
| 6 November 2026 | Gibbs David W | Director | Grant or award | +278 | — | 278 | Form 4 |
| 6 November 2026 | Holley Charles M | Director | Grant or award | +185 | — | 13,262 | Form 4 |
| 6 November 2026 | Ishrak Omar | Director | Grant or award | +152 | — | 7,682 | Form 4 |
| 13 August 2026 | Khosla Rachna | SVP, Business Development | Option exercise | +1,252 | $162.60 | 7,656 | Form 4 |
| 13 August 2026 | Khosla Rachna | SVP, Business Development | Open-market sale | −1,252 | $416.43 | 6,404 | Form 4 |
| 11 August 2026 | Khosla Rachna | SVP, Business Development | Open-market sale | −2,000 | $412.57 | 6,404 | Form 4 |
| 7 August 2026 | Busch Matthew C. | VP, Finance & CAO | Grant or award | +730 | — | 5,080 | Form 4 |
| 7 August 2026 | Drake Michael V | Director | Grant or award | +64 | — | 5,876 | Form 4 |
| 7 August 2026 | Holley Charles M | Director | Grant or award | +103 | — | 12,990 | Form 4 |
| 7 August 2026 | Ishrak Omar | Director | Grant or award | +85 | — | 7,486 | Form 4 |
| 6 August 2026 | Grygiel Nancy A. | SVP & Cco | Option exercise | +1,970 | $177.46 | 9,310 | Form 4 |
| 6 August 2026 | Grygiel Nancy A. | SVP & Cco | Open-market sale | −1,970 | $402.16 | 7,340 | Form 4 |
| 6 August 2026 | Grygiel Nancy A. | SVP & Cco | Option exercise | +1,000 | $177.31 | 8,340 | Form 4 |
| 6 August 2026 | Grygiel Nancy A. | SVP & Cco | Open-market sale | −1,000 | $402.16 | 7,340 | Form 4 |
| 6 August 2026 | Miller Derek | SVP, Human Resources | Option exercise | +2,069 | $162.60 | 14,531 | Form 4 |
| 6 August 2026 | Miller Derek | SVP, Human Resources | Open-market sale | −2,069 | $402.54 | 12,462 | Form 4 |
| 6 August 2026 | Miller Derek | SVP, Human Resources | Option exercise | +1,821 | $177.46 | 14,283 | Form 4 |
| 6 August 2026 | Miller Derek | SVP, Human Resources | Open-market sale | −1,821 | $402.54 | 12,462 | Form 4 |
| 19 May 2026 | Austin Wanda M | Director | Grant or award | +665 | — | 8,018 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Amgen page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.